Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of siltuximab vs methylprednisolone in hospitalized COVID-19 pneumonia
2020-001413-20Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siltuximab in coronavirus pneumonia (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: ICU admission proportion. Started Apr 2020; status: completed.
02
Drugs
siltuximab
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001413-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001413-20.